

What Do You Expect From Acute Treatments for Migraine?

Hear the perspectives of leading experts, as they discuss the potential for a novel therapy to address the challenges in disease management in one quick-dissolving dose.

Nurtec™ ODT
(rimegepant)
orally disintegrating tablets 75 mg

There are a number of unmet needs in the acute treatment of migraine, which often leave patients dissatisfied with suboptimal results. Given the staggering consequences of migraine, there is a need for acute therapy to help patients eliminate migraine pain and return to normal function.

Nurtec™ ODT (rimegepant) is a novel approach to addressing critical unmet needs in the acute treatment of migraine.

Take a closer look at the mechanism of action, comprehensive clinical trial program, and proven results that support the rapid and sustained response that Nurtec ODT can deliver in just 1 dose.

FEATURED VIDEOS

Nurtec ODT: A Novel Approach to Targeting Underlying Migraine Processes, With 1-Dose Delivery of Results



Nurtec ODT: Exploring the Comprehensive Clinical Trial Program Supporting Rapid & Sustained Efficacy



Nurtec ODT: Addressing Unmet Patient Needs With an Acute Treatment That Delivers Well-Tolerated Results



Visit www.treatmentperspectives.com/migraine/Biohaven for exclusive access to these expert discussions.

INDICATION

Nurtec™ ODT (rimegepant) is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use

Nurtec ODT is not indicated for the preventive treatment of migraine.

IMPORTANT SAFETY INFORMATION

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash, and can occur days after administration.

Adverse Reactions: The most common adverse reaction was nausea (2% in patients who received Nurtec ODT compared to 0.4% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.

Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A or inhibitors of P-gp or BCRP. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.

Use in Specific Populations: *Pregnant/breast feeding:* It is not known if Nurtec ODT can harm an unborn baby or if it passes into breast milk. *Hepatic impairment:* Avoid use of Nurtec ODT in persons with severe hepatic impairment. *Renal impairment:* Avoid use in patients with end-stage renal disease.

Please see full [Prescribing Information](#).

Nurtec is a trademark or a registered trademark of Biohaven Pharmaceuticals, Inc. BIOHAVEN and the Biohaven logo are trademarks or registered trademarks of Biohaven Pharmaceuticals, Inc.

© 2020 Biohaven Pharmaceuticals, Inc. New Haven, CT 06510.

US-RIMODT-2000215. 04/2020.